Curran Terrie
- SEC CIK
- 0001690298
In the past year, 2 open-market sale filings worth $984.0K and no purchases.
Current role at each company
- ARQT Arcutis Biotherapeutics, Inc.Directoras of Aug 28, 2026
- PHAT Phathom Pharmaceuticals, Inc.President and Chief Executiveas of Mar 3, 2025
- MYOV Myovant Sciences Ltd.Directoras of Mar 10, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $984.0K
- 2 filings
- Net
- −$984.0K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Curran Terrie as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ARQT Arcutis Biotherapeutics, Inc.
Director3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 13, 2024 (view filing) | Nov 11 | 2 days | Curran TerrieDirector | SSale | −8.69K | $10.85 | −$94.3K | −46.1%10.1K after | |
| Aug 24, 2026 (view filing)4:19 PM ET | Aug 20 | 4 days | Curran TerrieDirector | SSale | −1.07K | $26.04 | −$27.9K | −4.4%23.5K after | |
| Aug 28, 2026 (view filing)5:40 PM ET | Aug 27 | 1 day | Curran TerrieDirector | SSale | −38.2K | $25.03 | −$956.1K | −61.9%23.5K after | 2 lots |
PHAT Phathom Pharmaceuticals, Inc.
President and Chief Executive8 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 16, 2022 (view filing) | May 13 | 3 days | Curran TerriePresident and Chief Executive | PPurchase | +20.5K | $7.41 | +$151.9K | +46.5%64.6K after | |
| Nov 23, 2022 (view filing) | Nov 21 | 2 days | Curran TerriePresident and Chief Executive | SSale | −1.53K | $9.60 | −$14.6K | −1.8%83.7K after | |
| Jan 20, 2023 (view filing) | Jan 20 | Same day | Curran TerriePresident and Chief Executive | SSale | −5.82K | $8.20 | −$47.7K | −3.2%176.8K after | |
| Mar 3, 2023 (view filing) | Mar 1 | 2 days | Curran TerriePresident and Chief Executive | SSale | −1.44K | $8.54 | −$12.3K | −0.8%175.4K after | |
| Apr 7, 2023 (view filing) | Apr 6 | 1 day | Curran TerriePresident and Chief Executive | PPurchase | +12.9K | $7.82 | +$101.0K | +7.4%188.3K after | |
| Mar 26, 2024 (view filing) | Mar 22 | 4 days | Curran TerriePresident and Chief Executive | SSale | −16.9K | $9.11 | −$153.5K | −3.9%410.8K after | |
| Jul 17, 2024 (view filing) | Jul 15 | 2 days | Curran TerriePresident and Chief Executive | SSale | −33.8K | $11.72 | −$396.7K | −8.2%377.7K after | |
| Jan 23, 2025 (view filing) | Jan 21 | 2 days | Curran TerriePresident and Chief Executive | SSale | −19.1K | $6.59 | −$125.9K | −5.0%360.5K after |
MYOV Myovant Sciences Ltd.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2021 (view filing) | Sep 1-2 | 2 days | Curran TerrieDirector | SSale | −48.5K | $25.02 | −$1.21M | −100.0%0 after | 2 lots |
| Sep 13, 2021 (view filing) | Sep 9 | 4 days | Curran TerrieDirector | SSale | −4.85K | $25.58 | −$124.1K | −100.0%0 after |